Key result
Unfractionated heparin drives a ~7% absolute increase in platelet-monocyte aggregation via P-selectin.
Why the study?
Does unfractionated heparin increase platelet-monocyte aggregation compared to fractionated heparins or direct thrombin inhibitors in healthy volunteers and PCI patients?
Does unfractionated heparin increase platelet-monocyte aggregation compared to fractionated heparins or direct thrombin inhibitors in healthy volunteers and PCI patients?
Unfractionated heparin promotes proinflammatory platelet-monocyte aggregation via a P-selectin-dependent mechanism, providing a potential mechanistic explanation for the superior cardiovascular outcomes associated with fractionated heparins and direct thrombin inhibitors.
Answers are grounded in this paper and cite their sources.
May explain differential PCI outcomes with heparins; hypothesis-generating for P-selectin modulation in anticoagulation.
OBJECTIVES: To determine the in vitro effects of unfractionated heparin, fractionated heparin and direct thrombin inhibition on platelet-monocyte aggregation, and to establish the in vivo effects of unfractionated heparin and direct thrombin inhibition on platelet-monocyte aggregates in patients scheduled for percutaneous coronary intervention (PCI). DESIGN: Platelet-monocyte aggregates were assessed in whole blood from 18 healthy volunteers after the addition of unfractionated heparin (1 U/ml), enoxaparin (0.8 U/ml) or lepirudin (5.6 microg/ml), and in 28 patients scheduled for elective PCI before and after administration of 100 U/kg of unfractionated heparin or 0.75 mg/kg bivalirudin. The influence of P-selectin-mediated platelet-monocyte aggregation was assessed with specific blocking antibodies. RESULTS: Addition of unfractionated heparin in vitro was associated with a higher level of platelet-monocyte aggregates than in controls (20.1 (1.9)% v 16.2 (1.6)%, respectively, p < 0.001). However, platelet-monocyte aggregation was not affected by enoxaparin or lepirudin (16.9 (2.0)% and 17.0 (2.2)%, respectively, NS). Intravenous unfractionated heparin in vivo also resulted in an increase in platelet-monocyte aggregates (absolute Delta 7.1 (2.7)%, p < 0.01), whereas intravenous bivalirudin had no effect (absolute Delta -1.5 (2.4)%, NS). The addition of P-selectin blockade abolished any increase in platelet-monocyte aggregates associated with heparin. CONCLUSIONS: In vitro and in vivo unfractionated heparin is associated with increased platelet-monocyte aggregation through a P-selectin-dependent mechanism. These findings provide a potential explanation for the superior cardiovascular outcomes associated with fractionated heparins and direct thrombin inhibitors.
No takes yet. Share an insight, caveat, or question.
Harding et al. (2006) studied Scheduled for elective PCI (n=46). Unfractionated heparin vs. Controls (in vitro) and bivalirudin (in vivo) was evaluated on Platelet-monocyte aggregates (in vitro) (p=<0.001). Unfractionated heparin increased platelet-monocyte aggregation both in vitro and in vivo via a P-selectin mechanism.
Synapse has enriched 10 related papers. Consider them for comparative context: